LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. director James A. Johnson received a grant of stock options covering 28,000 shares of common stock. The options carry an exercise price of $9.54 per share and expire on April 8, 2036, and represent compensation rather than an open-market purchase.
These options are scheduled to vest monthly over 24 months on the monthly anniversaries of the grant date, as long as Johnson continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. The award vests monthly over 24 months, so Edelman earns portions of the grant gradually as he continues to serve as a service provider. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. reported that Chief Medical Officer Javier San Martin received a grant of stock options covering 350,000 shares of common stock. The options have an exercise price of $9.54 per share, expire on April 8, 2036, and were awarded as compensation.
According to the grant terms, the options vest in equal monthly installments over 48 months from the grant date, so long as San Martin continues to serve as a Service Provider under LeonaBio's 2026 Equity Incentive Plan. This is a derivative award, not an open-market purchase or sale.
LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was classified as a grant or other acquisition of a derivative security, with 300,000 options held directly after the transaction. According to the grant terms, the underlying shares are scheduled to vest monthly over 48 months, subject to his continued service as a provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. reported that its Chief Financial Officer, Robert Renninger, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
According to the grant terms, these options vest in equal monthly installments over 48 months from the grant date, contingent on Mr. Renninger continuing to serve as a service provider under LeonaBio's 2026 Equity Incentive Plan. Following this award, he holds 300,000 stock options directly.
LeonaBio, Inc. reported that President and CEO Mark James Litton received a grant of stock options for 750,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
These options were awarded as a compensation grant and will vest in equal monthly installments over 48 months, as long as he continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options covering 750,000 shares.
LeonaBio, Inc. is registering up to 5,502,402 shares of common stock for resale by Sermonix Pharmaceuticals, Inc., issuable upon exercise of a pre-funded warrant from a December 2025 licensing transaction. LeonaBio will not sell any shares in this offering and receives no resale proceeds.
The company will receive only the nominal cash exercise price of $0.001 per share, or about $5,502 in gross proceeds if the warrant is fully exercised. As of March 16, 2026, LeonaBio had 9,393,514 shares of common stock outstanding, and its stock traded at $8.42 per share on Nasdaq under the symbol “LONA.”
LeonaBio, Inc. is registering up to 58,464,567 shares of common stock for resale by existing investors under a Form S-1 converted from a prior Form S-3. These shares include stock already issued and shares issuable from pre-funded warrants and other warrants held by December 2025 private placement investors.
LeonaBio will not sell any shares in this offering and will not receive proceeds from selling stockholders’ resales. It may receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share, and approximately $146,249,987 from cash exercises of warrants on 23,031,494 underlying shares at $6.35 per share. As of March 16, 2026, 9,393,514 shares of common stock were outstanding, and the stock traded at $8.42 on Nasdaq under the symbol LONA.
LeonaBio, Inc. filed a second amendment to an earlier report to align with SEC guidance treating its Sermonix transaction as an acquisition of a business. The company obtained a waiver from certain financial statement requirements in exchange for providing expanded qualitative and cash expenditure disclosures.
The amendment details historical unaudited cash spending on the ELAINE-3 Study, including about $14 million, $12 million and $5 million by Sermonix in 2023, 2024 and part of 2025, and approximately $11 million by LeonaBio from December 18 through December 31, 2025. LeonaBio now expects to spend about $45 million in 2026 and $30 million in 2027 as it broadens the study scope.
The company has increased the ELAINE-3 Study intensity, expanded the contract research organization’s responsibilities, and plans to raise the sample size from 500 to up to 600 participants. It currently expects to complete enrollment in the fourth quarter of 2026 and release topline data in the second half of 2027.
LeonaBio, Inc. reported full-year 2025 results and highlighted a major strategic shift toward oncology and neurodegeneration. For the year ended December 31, 2025, cash, cash equivalents and investments rose to $88.3 million from $51.3 million, helped by a $90 million private placement of common stock and warrants that could bring in up to an additional $146 million if fully exercised.
Research and development expenses increased to $85.6 million, mainly from $68.1 million of acquired in‑process R&D tied to the lasofoxifene license, while general and administrative expenses fell to $16.7 million. Net loss widened modestly to $105.6 million, or $24.70 per share, compared with $96.9 million, or $25.19 per share, in 2024.
The company acquired an exclusive global license (excluding Asia and certain Middle East countries) to late‑stage breast cancer drug candidate lasofoxifene and is running the Phase 3 ELAINE‑3 trial, expecting enrollment completion in 4Q 2026 and topline data in 2H 2027. Its ALS candidate ATH‑1105 showed favorable Phase 1 safety and CNS penetration, with a Phase 2 proof‑of‑concept study in ALS planned to start in the second half of 2026.